Business, energy, technology, markets and global industry news from Business News Today

pembrolizumab

PharmaDeviceNews pembrolizumab
A representative image of bladder cancer treatment. As PADCEV and Keytruda show promise in transforming perioperative care, new platinum-free regimens are reshaping how muscle-invasive bladder cancer is managed.
Pharma & Biotech

PADCEV plus Keytruda meets survival endpoints in cisplatin-eligible bladder cancer patients

Astellas Pharma Inc. and Pfizer Inc. have announced that their antibody-drug conjugate PADCEV (enfortumab vedotin), in combination with the PD-1 inhibitor pembrolizumab (marketed as Keytruda by Merck), met key survival endpoints in the Phase 3 EV-304 trial. In cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC), the combination significantly improved both event-free survival and overall survival

Read More
Pharma & Biotech

How Anixa’s breast cancer vaccine could change immunoprevention strategies

Anixa Biosciences Inc. has reported final Phase 1 results for its investigational breast cancer vaccine targeting the α-lactalbumin protein, showing that the primary endpoints were met and 74 percent of participants demonstrated protocol-defined immune responses. The data were presented at the 2025 San Antonio Breast Cancer Symposium and build the case for a Phase 2

Read More